XenoPort promotes Angotti and Bates; slims down workforce
This article was originally published in Scrip
XenoPort, a biopharmaceutical company focused on neurological disorders, has promoted Vincent Angotti to the role of executive vice-president and COO and Gregory Bates to senior vice-president of regulatory affairs and quality. Mr Angotti was previously senior vice-president and chief commercialisation officer, while Mr Bates was vice-president of regulatory affairs.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.